Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Kelun-Biotech announces breakthrough therapy designation granted for Sacituzumab tirumotecan (Sac-TMT) in combination with Tagitanlimab in China for certain types of Non-Small Cell Lung Cancer Sichuan Kelun-Biotech’s TROP2-directed […]
Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer Daiichi Sankyo and AstraZeneca have initiated […]
Weekly Digest – June 2025 Weekly Digest – June 2025 11 June 2025: Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services Simtra BioPharma Solutions and MilliporeSigma (Merck KGaA’s Life […]
Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates Medicovestor and Sanyou Biopharmaceuticals have formed a strategic partnership to co-develop first-in-class chemoimmunotherapy antibody-drug […]
Weekly Digest – June 2025 Weekly Digest – June 2025 06 June 2025: OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMine Enabling Technologies OBI Pharma and TegMine Therapeutics have entered a Master Services Agreement to collaborate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: SK plasma enters ADC cancer drug development with AIMEDBIO partnership SK plasma has partnered with AIMEDBIO to co-develop an antibody-drug conjugate (ADC) targeting ROR1, marking SK plasma […]
Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: European Commission approves ADCETRIS (Brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV hodgkin lymphoma in combination with ECADD Takeda’s ADCETRIS-based regimen BrECADD […]
Weekly Digest – June 2025 Weekly Digest – June 2025 02 June 2025: Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting Eli Lilly’s FRα-targeting ADC (LY4170156) […]
Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: Avenzo Therapeutics initiates Phase 1/2 clinical study of AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody drug conjugate Avenzo Therapeutics has initiated a Phase 1/2 clinical trial for […]
Weekly Digest – June 2025 Weekly Digest – June 2025 31 May 2025: Trodelvy plus Keytruda reduces risk of disease progression or death by 35% versus Keytruda and chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer Gilead reported that Trodelvy […]
